Department of Clinical Nutrition, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Children's Hospital Aschaffenburg-Alzenau, Aschaffenburg, Germany.
Epilepsia Open. 2024 Jun;9(3):1096-1102. doi: 10.1002/epi4.12942. Epub 2024 Apr 20.
The ketogenic diet (KD) can have a negative impact on the linear growth and body composition of children. The aims of this study were to review two centers' experience with children who developed height deceleration on the KD and determine if the height deceleration was secondary to growth hormone deficiency (GHD), and if growth hormone therapy (GHT) would be effective and safe (not altering ketosis or seizure frequency). Retrospective chart reviews were performed on patients with KD referred to Endocrinology between 2013 and 2018. Seventeen children were identified. Data reviewed included: demographics, growth velocity, KD ratio, protein/calorie intake, lab results, GH dosage, Tanner stage, and seizure frequency, and endocrine recommendations. Descriptive statistics were performed. Of the 17 children referred to the Endocrine Division, seven children were growth hormone deficient and began GHT. Data were provided for six patients (2 males, 4 females; age 2-7 years at the start of KD) on the KD for >6 years and on GHT for >4 years. Growth for all patients stabilized or increased. IGF-1 z-scores normalized. GHT did not affect seizure frequency or ketosis. GHT in those with GHD can be an appropriate option allowing better growth while still maintaining ketogenic therapy and seizure control. PLAIN LANGUAGE SUMMARY: The KD can be an effective treatment for difficult-to-control epilepsy and some disorders of carbohydrate metabolism. The KD can adversely affect the linear growth (height) of children. This case series reviewed six patients who had slow linear growth. It was found that all six children had growth hormone deficiency, grew better with growth hormone treatments, and that their seizures and ketone levels were not affected.
生酮饮食(KD)会对儿童的线性生长和身体成分产生负面影响。本研究的目的是回顾两个中心在 KD 中出现身高减速的儿童的经验,并确定身高减速是否是由于生长激素缺乏(GHD)引起的,以及生长激素治疗(GHT)是否有效和安全(不会改变酮症或癫痫发作频率)。对 2013 年至 2018 年间内分泌科就诊的 KD 患儿进行回顾性图表回顾。确定了 17 名儿童。回顾的数据包括:人口统计学资料、生长速度、KD 比值、蛋白质/热量摄入、实验室结果、GH 剂量、Tanner 分期和癫痫发作频率以及内分泌建议。进行了描述性统计分析。在转至内分泌科的 17 名儿童中,有 7 名儿童生长激素缺乏并开始接受 GHT。为 6 名患者(2 名男性,4 名女性;KD 开始时年龄为 2-7 岁)提供了在 KD 上>6 年和 GHT 上>4 年的数据。所有患者的生长均稳定或增加。IGF-1 z 评分正常化。GHT 不影响癫痫发作频率或酮症。在 GHD 患者中,GHT 可以是一个合适的选择,允许更好的生长,同时仍维持生酮治疗和癫痫控制。
KD 可以是治疗难治性癫痫和某些碳水化合物代谢紊乱的有效方法。KD 会对儿童的线性生长(身高)产生不利影响。本病例系列回顾了 6 名生长缓慢的患儿。结果发现,所有 6 名儿童均存在生长激素缺乏症,生长激素治疗后生长情况更好,且癫痫发作和酮症水平不受影响。